Addison Advisors’s ADMA Biologics ADMA Stock Holding History

Addison Advisors’s Portfolio ADMA Stock Details ADMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$4.5K	Hold	500	–	–	﹤0.01%	743
2025 Q4	$9.12K	Hold	500	–	–	﹤0.01%	639
2025 Q3	$7.33K	Hold	500	–	–	﹤0.01%	665
2025 Q2	$9.11K	Hold	500	–	–	﹤0.01%	634
2025 Q1	$9.92K	Hold	500	–	–	﹤0.01%	584
2024 Q4	$8.57K	Hold	500	–	–	﹤0.01%	607
2024 Q3	$9.99K	Hold	500	–	–	﹤0.01%	595
2024 Q2	$5.59K	Hold	500	–	–	﹤0.01%	622
2024 Q1	$3.3K	Hold	500	–	–	﹤0.01%	598
2023 Q4	$2.26K	Hold	500	–	–	﹤0.01%	618
2023 Q3	$1.79K	Hold	500	–	–	﹤0.01%	598
2023 Q2	$1.84K	Hold	500	–	–	﹤0.01%	567
2023 Q1	$1.66K	Hold	500	–	–	﹤0.01%	561
2022 Q4	$1.94K	Hold	500	–	–	﹤0.01%	562
2022 Q3	$1K	Buy	+500	New	+$1.2K	﹤0.01%	579

Other funds holding ADMA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Addison Advisors's ADMA Position: Q1 2026 in Review

Addison Advisors held its ADMA Biologics (ADMA) position steady in Q1 2026 at 500 shares worth $4.5K. The position accounts for ﹤0.01% of the portfolio, ranked #743.

Addison Advisors first reported a position in ADMA in Q3 2022 and has held it in 15 quarters since. The position peaked at $9.99K in Q3 2024. 356 funds tracked by Wall St. Rank hold ADMA as of Q1 2026.

Addison Advisors held 500 shares of ADMA Biologics worth $4.5K as of Q1 2026.
Addison Advisors left its ADMA Biologics share count unchanged in Q1 2026.
ADMA Biologics made up ﹤0.01% of Addison Advisors's portfolio in Q1 2026, its #743 holding.
Addison Advisors first reported a position in ADMA Biologics in Q3 2022 and has held it in 15 quarters since.
Addison Advisors's ADMA Biologics position peaked at $9.99K in Q3 2024.
356 funds tracked by Wall St. Rank held ADMA Biologics as of Q1 2026.

Based on Addison Advisors's 13F filing for Q1 2026, filed 8 May 2026.